In direct compression lines handling diazepam pharma grade API at unit doses of 2–10 mg per tablet, content uniformity is governed by interparticle segregation forces rather than by chemical incompatibility. The API is typically milled or micronized so that the particle size distribution yields a D90 at or below 45 µm when measured by laser diffraction under USP <429>. A low-dose preblend is prepared by geometric dilution with lactose monohydrate or microcrystalline cellulose, then passed through a 30-mesh screen before transfer to an IBC bin blender. Blend rotation speed is commonly set between 6 rpm and 12 rpm for 10–20 min, with sampling at three depths according to an in-process blend uniformity protocol. The acceptance value for finished tablet uniformity is calculated under USP <905>; the compendial limit is L1 = 15.0, but low-dose diazepam batches are typically released with an average acceptance value below 10.0 to accommodate process drift. Direct compression blends require a compressibility index below 20% and a flow rate above 10 g/s through a 10 mm orifice under USP <1174>, otherwise tablet weight variation triggers high rejection rates at the press. Magnesium stearate is limited to 0.5–1.0% w/w; prolonged blending above 5 min after addition of the lubricant produces a hydrophobic film that retards dissolution. The tablet press is operated with a forced feeder and pre-compression roll, and the main compression force is typically adjusted between 5 kN and 12 kN depending on tooling diameter and final hardness. Hardness is measured after 24 h at 25 °C/60% RH to allow elastic recovery. Tablet friability is required to be below 1.0% under USP <1216>; hardness is often set between 4–8 kp for 8–10 mm flat-faced beveled tablets to balance disintegration. Disintegration testing under USP <701> is performed in water at 37 °C; the specification is complete disintegration within 15 min unless otherwise stated. Dissolution release testing is carried out under USP <711> using Apparatus 2 at 50 rpm with a suitable aqueous medium; sampling times and Q values follow the applicable monograph. Environmental conditions are held at 20–25 °C and 35–45% RH to reduce static charging; higher humidity introduces moisture into hygroscopic fillers and can alter weight control.

What Capsule Filling Parameters Prevent Low-Dose Segregation?

A low-dose diazepam capsule fill is normally produced through a preblend containing a diluent such as pregelatinized starch or lactose monohydrate, a glidant such as colloidal silicon dioxide at 0.2–0.5% w/w, and a low-residue lubricant. The fill weight for a size 3 or 4 capsule is often set between 80 mg and 140 mg, and the API fraction may be below 5% by weight. Tamping-pin and dosing-disc capsule filling machines require stable powder bed height; segregation can occur inside the hopper if the blend contains wide particle size differences between API and diluent. Fill weight control is monitored by periodic sampling at 15–30 min intervals during an encapsulation run. Empty capsule shells, whether gelatin or HPMC, must be conditioned to 12–15% moisture for gelatin and 4–7% moisture for HPMC to prevent brittleness. The encapsulation room is maintained at 40–55% RH to reduce triboelectric charging while avoiding softening of gelatin shells. Content uniformity is assessed by USP <905> on finished capsules; dissolution is assessed by USP <711> with a suitable aqueous medium. If dissolution is delayed by hydrophobic glidants, reformulation with a disintegrant such as crospovidone at 2–4% w/w is required. Batch records typically specify that the capsules be de-dusted and metal-checked after filling, then stored in tight, light-resistant containers at 20–25 °C.

When high-shear wet granulation is selected for diazepam oral granules intended for sachet filling or subsequent tablet compression, the choice of granulating fluid influences the hydrolytic degradation pathway. Diazepam undergoes acid-catalyzed hydrolysis to 2-methylamino-5-chlorobenzophenone; therefore, aqueous granulation with acidic binders or prolonged exposure to low-pH solutions is avoided. Because the API is practically insoluble in water, a hydroalcoholic granulation fluid containing ethanol and purified water is often used with povidone K30 as a binder. The high-shear granulator is operated with impeller speed between 200 rpm and 400 rpm and chopper speed between 1500 rpm and 3000 rpm; the wet mass endpoint is reached when the torque curve plateaus for 30–60 s. Overgranulation produces dense granules with delayed disintegration and slower dissolution. The wet granules are dried in a fluid bed dryer with inlet air temperature between 50 °C and 60 °C; product temperature should not exceed 40 °C to minimize degradation. Residual moisture is controlled to 1.5–2.5% w/w by Karl Fischer titration. After drying, granules are screened through a 1.0 mm mesh, and the target granule D50 is typically 150–250 µm when measured by sieve analysis. Granules intended for sachet filling must meet flow and content uniformity specifications under USP <905>, and dissolution profiling under USP <711> is used to confirm that granulation did not introduce a formulation-dependent lag time.

Solvent-Based Injectable Vehicle Precipitation and pH Boundaries

Commercial diazepam injection is not a simple aqueous solution; the drug substance is practically insoluble in water, and the injectable product uses a parenteral vehicle based on organic solvents. The pH of the finished injection is typically specified between 6.2 and 6.9; outside this range, the benzodiazepine lactam ring becomes prone to hydrolytic opening. The vehicle commonly includes propylene glycol, ethyl alcohol, benzyl alcohol, and a benzoate buffer system; quantitative ratios are product-specific and are validated through stability and precipitation studies. Because diazepam has poor water solubility, dilution of the injection with normal saline or lactated Ringer solution can produce visible precipitation within minutes. The product is therefore administered either undiluted by slow intravenous push or by deep intramuscular injection. Polyvinyl chloride tubing and containers are avoided because diazepam partitions into PVC; glass or polyolefin containers are used for administration. Sterility is established by aseptic processing or terminal sterilization under conditions that do not increase the benzophenone degradant above the specification limit. Bacterial endotoxin limits are calculated from USP <85> based on the maximum dose rate and route; particulate matter is controlled to USP <788> for injections. The fill line uses depyrogenated vials, inert nitrogen overlay, and membrane filtration through a 0.22 µm filter when solution viscosity permits. Release testing includes clarity under visible light, pH by USP <791>, and residual solvent limits under USP <467> and ICH Q3C.

For dry granulation by roller compaction of diazepam granules intended for oral unit-dose containers, a solvent-free process eliminates the hydrolytic risk associated with aqueous granulation and avoids residual-solvent compliance under ICH Q3C. The diazepam API is pre-blended with microcrystalline cellulose, crospovidone, and colloidal silicon dioxide; magnesium stearate is added either before or after compaction depending on whether post-compaction granulation slows dissolution. The roller compactor is operated with a roll gap of 2–3 mm and a hydraulic pressure determined by factorial design; published data for this specific configuration is limited, so process characterization is batch-specific. Ribbons are milled through a 0.8–1.0 mm screen to produce granules with a D50 of 180–250 µm, which reduces segregation potential during sachet filling. Content uniformity is assessed by USP <905>, and dissolution release testing under USP <711> is required to confirm that the dry granulation route does not generate overly dense granules with slow disintegration. Because dry granulation can increase the crystalline surface area, the process is monitored for bulk density and compressibility index under USP <616> before final filling. Packaging in light-resistant laminated foil sachets at 20–25 °C protects the API from light and moisture.